High-throughput genetic screening can discern persistence factors by repeatedly stimulating T cells with anti-CD3/CD28 and IL-2 in vitro, or by implanting them into tumor-bearing mice and comparing chronically stimulated T cells with unstimulated counterparts [30, 59–61]. Here, CD28 is linked to neoplasm.